-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Bio's Non-GLP Toxicology Platform
Author:
InnoModels
Release time:
2024-09-18
In the vast world of drug development, safety and efficacy are always the two core issues that developers are most concerned about. Toxicology evaluation, as a key link in the process of new drug development, has a direct bearing on the accuracy and reliability of the drug, whether the drug can enter the clinical trial or even go on the market. With its non-GLP (Good Laboratory Practice) toxicology platform, InnoModels Biotechnology (Beijing) Co., Ltd. plays a pivotal role in the field of drug discovery and development, providing a strong safety guarantee for new drug developers.
Platform Advantages Overview
InnoModels Bio's non-GLP toxicology platform stands out in the industry with its significant advantages. Firstly, the platform adopts advanced testing technology and equipment to ensure the accuracy and reliability of the experimental results. This not only improves the precision of experimental data, but also provides a solid foundation for subsequent drug development decisions.
Secondly, the platform has an experienced and skilled team. The project director has more than 5 years of GLP toxicology-related experience, while the experimental team has at least 3 years of related work experience. Meanwhile, the professional pathology team includes pathologists holding the American College of Veterinary Pathologists License (ACVP) and top pathology professors in China, which provides authoritative pathology support for the toxicity assessment of drugs.

Comprehensive Toxicology Evaluation Services
InnoModels Bio's non-GLP toxicology platform is able to provide comprehensive toxicology assessment services covering acute, chronic, reproduction and carcinogenicity to meet the different needs of our clients at different stages of research and development. Specific services include but are not limited to:
- Single Administration Toxicity Test: Evaluate the toxicity response of a drug after single administration and provide preliminary data for the safety assessment of the drug.
- Repeated administration toxicity test: To observe the long-term toxicity reaction of the drug through repeated administration, and to provide the basis for the evaluation of the long-term safety of the drug.
- Toxicokinetic test: to study the absorption, distribution, metabolism and excretion of drugs in the organism, and to understand the dynamic changes of drugs in the body.
- Histopathology evaluation: including H.E. staining, film reading and pathology report preparation, peer review by pathology experts to ensure the professionalism and accuracy of the evaluation results.
Application Cases and Effectiveness
The non-GLP toxicology platform has played a key role in several new drug development projects. For example, a new drug development project required a comprehensive safety assessment before entering clinical trials. The InnoModels Biotechnology platform provided professional toxicology services for the project, including acute toxicity, long-term toxicity, reproductive developmental toxicity and other aspects of the study. Through the evaluation of the platform, the safety and efficacy of the new drug was fully verified, providing a strong guarantee for the smooth progress of the clinical trial.
Innovation and Upgrading
In the face of increasingly fierce market competition and technological innovation, InnoModels' non-GLP toxicology platform has always been innovative and upgraded. The platform actively introduces international advanced testing technologies and equipments, and constantly improves its technical strength and service level. At the same time, InnoModels Biotechnology also continuously optimizes the experimental process and standard operating procedures to ensure the accuracy and reliability of the experimental results.
Conclusion
With its advanced testing technology and equipment, professional team and comprehensive toxicology evaluation services, the non-GLP toxicology platform of InnoModels Biotechnology has won the trust and praise of customers in the field of drug discovery and development. In the future, with the continuous development of the biopharmaceutical field, the non-GLP toxicology platform will play an even more important role in drug discovery and development, and escort the success of new drug discovery and development. InnoModels Biotechnology will continue to uphold the concept of "Innovation, Professionalism, Reliability", and is committed to providing a new generation of experimental animal models and technical support closer to the clinic for the research and development of oncology and tumor immunotherapy, and contributing to the rapid development of the new drug R&D industry.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd